This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Does Anavex Life Sciences (AVXL) Have the Potential to Rally 265% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 265% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is the Options Market Predicting a Spike in Anavex (AVXL) Stock?
by Zacks Equity Research
Investors need to pay close attention to Anavex (AVXL) stock based on the movements in the options market lately.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Anavex (AVXL) to Report Q3 Earning: What's in the Cards?
by Zacks Equity Research
On Anavex's (AVXL) earnings call for the fiscal third quarter, investor focus will mainly be on the company's progress with its lead investigational candidate for Alzheimer's disease.
Company News for Jun 29, 2021
by Zacks Equity Research
Companies in the news are: NTLA, AVXL, MNKD, KYMR
Biotech Stock Roundup: BIIB's AD Drug Update, CVAC's Decline on Vaccine Data & More
by Zacks Equity Research
The biotech sector was in focus last week with pipeline updates from Biogen (BIIB) and CureVac (CVAC), among others.
Implied Volatility Surging for Anavex Life Sciences (AVXL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Anavex Life Sciences (AVXL) stock based on the movements in the options market lately.
Company News for Jun 15, 2021
by Zacks Equity Research
Companies In The News Are: RIDE, PHG, AVXL, RDS.A
Anavex Life Sciences (AVXL) Just Reclaimed the 50-Day Moving Average
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?
Why Anavex Life Sciences (AVXL) Might Surprise This Earnings Season
by Zacks Equity Research
Anavex Life Sciences (AVXL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Alzheimer's Disease: 5 Stocks on Biotech Radars
by Kevin Cook
While Biogen rides a big-cap rollercoaster, a few small players are creating better trading opps.
Deciphera (DCPH) Reports Narrower-Than-Expected Q4 Loss
by Zacks Equity Research
Deciphera Pharmaceuticals (DCPH) reports narrower-than-expected loss. Nonetheless, sales marginally surpass estimates for the fourth quarter of 2020.
Implied Volatility Surging for Anavex Life Sciences (AVXL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Anavex Life Sciences (AVXL) stock based on the movements in the options market lately.
Alexion (ALXN) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) beats earnings and sales estimates for the fourth quarter of 2020.
Biotech Bonanza: COVID Launches Science at Warp Speed
by Kevin Cook
From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.
Horizon Therapeutics (HZNP) to Acquire Viela Bio for $3.05B
by Zacks Equity Research
Horizon Therapeutics (HZNP) is set to buy Viela Bio for $3.05 billion to expand its pipeline and accelerate growth.
Abbott's (ABT) Nutrition & Diabetes Care Beat COVID-19 Woes
by Zacks Equity Research
Within pediatric nutrition, Abbott (ABT) registers U.S. sales growth led by increased market share of Similac infant formula brand.
Incyte (INCY) Gets Positive CHMP Opinion for Pemigatinib
by Zacks Equity Research
Incyte's (INCY) pemigatinib gets positive CHMP opinion by the EMA for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion.
Dr. Reddy's (RDY) Q3 Earnings Decline Y/Y, Sales Increase
by Zacks Equity Research
Dr. Reddy's (RDY) earnings decline while sales grow year over year in third-quarter fiscal 2021.
Illumina (ILMN) New Collaboration to Aid Genomics Startups
by Zacks Equity Research
Illumina (ILMN) partners with Sequoia Capital China to set up a genomics-focused startup incubator in China.
Global Blood's (GBT) MAA for Oxbryta Accepted in Europe
by Zacks Equity Research
Global Blood's (GBT) Marketing Authorization Application for the label expansion of Oxbryta tablets has been accepted by the European Medicines Agency.
Vertex's (VRTX) Trikafta NDA Gets Priority Review by FDA
by Zacks Equity Research
Vertex's (VRTX) sNDA seeking approval for Trikafta to treat cystic fibrosis in children has been accepted by the FDA.
Axsome's (AXSM) Migraine Drug Shows Long-Term Safety in Study
by Zacks Equity Research
Axsome (AXSM) posts favorable data from the long-term phase III study evaluating AXS-07 for acute treatment of migraine. The company also begins a second phase III study on AXS-05 for AD agitation.
Anavex Life Sciences (AVXL) Upgraded to Buy: Here's Why
by Zacks Equity Research
Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.